Ixazomib
Multiple Myeloma
.svg)
Drug Status
Government Approvals
US(FDA), UK(BNF)
WHO Essential Medicine
NO
Known Teratogen
No
Pharmaceutical Class
Proteasome Inhibitor
Controlled Drug Substance
No
Ixazomib
Summary
Ixazomib is used in combination with other medications to treat multiple myeloma, a type of cancer that affects plasma cells in your bone marrow. It is typically used in patients who have already undergone at least one prior therapy.
Ixazomib is a type of drug called a proteasome inhibitor. It works by blocking the action of proteasomes, which are protein complexes that break down unneeded or damaged proteins in cells. By doing this, Ixazomib disrupts the normal function of cancer cells, leading to their death and helping to control the progression of multiple myeloma.
The usual dose of Ixazomib for adults is 4 mg taken once a week on Days 1, 8, and 15 of a 28-day treatment cycle. It is taken orally, by swallowing the capsules whole with water.
Common side effects of Ixazomib include diarrhea, constipation, nausea, vomiting, and peripheral neuropathy (nerve damage resulting in pain or numbness). More serious adverse effects can include low platelet count, liver damage, and blood clotting disorders.
Ixazomib can cause fetal harm, so it should not be taken by pregnant women. Women of reproductive potential should use effective contraception during treatment and for 90 days after the last dose. It is also not recommended for breastfeeding women. Ixazomib is contraindicated in patients with hypersensitivity to the active substance or any of its components.
Indications and Purpose
How does Ixazomib work?
Ixazomib is a proteasome inhibitor that works by blocking the action of proteasomes, which are protein complexes that break down unneeded or damaged proteins. By inhibiting the proteasome, Ixazomib disrupts the normal function of cancer cells, leading to their death and helping to control the progression of multiple myeloma.
Is Ixazomib effective?
The efficacy of Ixazomib was evaluated in a randomized, double-blind, placebo-controlled study in patients with relapsed and/or refractory multiple myeloma. The study showed a statistically significant improvement in progression-free survival for patients treated with Ixazomib in combination with lenalidomide and dexamethasone compared to placebo.
What is Ixazomib?
Ixazomib is used in combination with lenalidomide and dexamethasone to treat multiple myeloma in patients who have received at least one prior therapy. It belongs to a class of medications called proteasome inhibitors, which work by helping to kill cancer cells. Ixazomib inhibits the proteasome, a protein complex that breaks down unneeded or damaged proteins, thereby disrupting cancer cell growth and survival.
Directions for Use
For how long do I take Ixazomib?
Ixazomib is typically used in cycles of 28 days, with the medication taken on Days 1, 8, and 15. Treatment continues until disease progression or unacceptable toxicity occurs. The exact duration will depend on individual response and tolerance.
How do I take Ixazomib?
Ixazomib should be taken on an empty stomach, at least 1 hour before or 2 hours after eating. Swallow the capsules whole with water, and do not crush, chew, or open them. Avoid taking Ixazomib and dexamethasone at the same time, as dexamethasone should be taken with food.
How long does it take for Ixazomib to start working?
The median time to response for Ixazomib is approximately 1.1 months. However, the exact time it takes to start working can vary depending on individual factors and the specific condition being treated.
How should I store Ixazomib?
Store Ixazomib at room temperature, not above 30°C (86°F), and do not freeze. Keep the medication in its original packaging until just before use to protect it from moisture. Ensure it is out of reach of children and pets.
What is the usual dose of Ixazomib?
The usual dose of Ixazomib for adults is 4 mg taken once a week on Days 1, 8, and 15 of a 28-day treatment cycle. There is no established dose for children as the safety and effectiveness of Ixazomib in pediatric patients have not been established. Always follow your doctor's advice for dosing.
Warnings and Precautions
Can I take Ixazomib with other prescription drugs?
Avoid concomitant administration of Ixazomib with strong CYP3A inducers like rifampin, phenytoin, carbamazepine, and St. John's Wort, as they can reduce the effectiveness of Ixazomib. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.
Can Ixazomib be taken safely while breastfeeding?
It is not known if Ixazomib passes into breast milk. Due to the potential for serious adverse reactions in breastfed infants, women are advised not to breastfeed during treatment with Ixazomib and for 90 days after the last dose.
Can Ixazomib be taken safely while pregnant?
Ixazomib can cause fetal harm when administered to a pregnant woman. Women of reproductive potential should use effective contraception during treatment and for 90 days after the last dose. If pregnancy occurs, contact your doctor immediately. There is no strong evidence from human studies, but animal studies have shown reproductive toxicity.
Is it safe to exercise while taking Ixazomib?
Ixazomib may cause side effects like extreme tiredness and peripheral neuropathy, which could potentially limit the ability to exercise. If you experience these symptoms, consult your doctor for advice on managing them and adjusting your activity levels.
Is Ixazomib safe for the elderly?
No overall differences in safety or effectiveness were observed between elderly patients and younger patients. However, greater sensitivity of some older individuals cannot be ruled out. Elderly patients should be monitored closely for side effects, and dose adjustments may be necessary based on individual tolerance and response.
Who should avoid taking Ixazomib?
Important warnings for Ixazomib include the risk of thrombocytopenia, gastrointestinal toxicities, peripheral neuropathy, and hepatotoxicity. Patients should be monitored for these conditions, and dose adjustments may be necessary. Ixazomib is contraindicated in patients with hypersensitivity to the active substance or any of its excipients.
